Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction. Issue 3 (March 2015)

• Record Type: Journal Article
• Authors: Ramos, F.; Thépot, S.; Pleyer, L.; Maurillo, L.; Itzykson, R.; Bargay, J.; Stauder, R.; Venditti, A.; Seegers, V.; Martínez-Robles, V.; Burgstaller, S.; Récher, C.; Debén, G.; Gaidano, G.; Gardin, C.; Musto, P.; Greil, R.; Sánchez-Guijo, F.; Fenaux, P.; for the European ALMA Investigators, 1
• Is Part Of: Leukemia research. Volume 39:Issue 3(2015:Mar.)
• Page Start: 296
• Page End: 306
• Publication Date: 2015-03
• Subjects: Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2014.12.013
• Languages: English
• ISSNs: 0145-2126

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">European ALMA score (E-ALMA) takes into consideration ECOG, WBC and cytogenetics.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">It may be used in unfit WHO-defined AML patients treated frontline with azacitidine.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Its design involved 371 unfit AML patients treated in 4 European countries.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">AZA may be a good choice for patients with a favorable or intermediate E-ALMA score.</p> </list-item> </list> </p> </sec> </abstract>